tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Inflammatory Bowel Diseases D015212 9 associated lipids
Reperfusion Injury D015427 65 associated lipids
Colitis D003092 69 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Fatty Liver D005234 48 associated lipids
Cataract D002386 34 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Body Weight D001835 333 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Thomson AW et al. FK 506, cardiac transplantation, and graft-vessel disease. 1992 Lancet pmid:1370563
First MR Transplantation in the nineties. 1992 Transplantation pmid:1370734
Naito M et al. Reversal of multidrug resistance by an immunosuppressive agent FK-506. 1992 Cancer Chemother. Pharmacol. pmid:1370765
Yem AW et al. The Hsp56 component of steroid receptor complexes binds to immobilized FK506 and shows homology to FKBP-12 and FKBP-13. 1992 J. Biol. Chem. pmid:1371107
Park ST et al. PPIase catalysis by human FK506-binding protein proceeds through a conformational twist mechanism. 1992 J. Biol. Chem. pmid:1371117
Bishop DK and Li W Cyclosporin A and FK506 mediate differential effects on T cell activation in vivo. 1992 J. Immunol. pmid:1371128
Hatfield SM and Roehm NW Cyclosporine and FK506 inhibition of murine mast cell cytokine production. 1992 J. Pharmacol. Exp. Ther. pmid:1371158
Takaya S et al. The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors. 1992 Transplantation pmid:1371195
Francavilla A et al. Inhibition of liver, kidney, and intestine regeneration by rapamycin. 1992 Transplantation pmid:1371198
Matsukawa W et al. Effects of a new immunosuppressive agent, FK506, in rats with active Heymann nephritis. 1992 J. Lab. Clin. Med. pmid:1371298
Sampson BA and Gotschlich EC Neisseria meningitidis encodes an FK506-inhibitable rotamase. 1992 Proc. Natl. Acad. Sci. U.S.A. pmid:1371354
Andersson J et al. Effects of FK506 and cyclosporin A on cytokine production studied in vitro at a single-cell level. 1992 Immunology pmid:1371491
Strasser S et al. Effect of FK506 on insulin secretion in normal dogs. 1992 Metab. Clin. Exp. pmid:1371575
Kim YI et al. Stimulation of liver regeneration by pretreatment with azathioprine as well as cyclosporine and FK506. 1992 Transplantation pmid:1373539
Carobbi A et al. Synergism of splenectomy and immunosuppressive drugs in prolongation of cardiac xenograft survival. 1992 Transplant. Proc. pmid:1373543
Ueno M et al. Immunosuppressive effect in combination therapy of cyclosporine A, FK 506, and 15-deoxyspergualin on pancreatic islet xenotransplantation. 1992 Transplant. Proc. pmid:1373546
Matsuzaki T et al. Liver transplantation for diethylnitrosamine-induced hepatocellular carcinoma in rats. 1992 Transplant. Proc. pmid:1373547
Vincent SH et al. In vitro metabolism of FK-506 in rat, rabbit, and human liver microsomes: identification of a major metabolite and of cytochrome P450 3A as the major enzymes responsible for its metabolism. 1992 Arch. Biochem. Biophys. pmid:1373595
Liu J et al. Inhibition of T cell signaling by immunophilin-ligand complexes correlates with loss of calcineurin phosphatase activity. 1992 Biochemistry pmid:1373650
Adachi A et al. Immunosuppressive effect of FK506 on experimental allergic neuritis in Lewis rats: change of T cell subsets. 1992 Intern. Med. pmid:1373661
Fruman DA et al. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. 1992 Proc. Natl. Acad. Sci. U.S.A. pmid:1373887
Lake JR et al. Maintenance immunosuppression after liver transplantation. 1992 Semin. Liver Dis. pmid:1373916
Taormina D et al. Stability and sorption of FK 506 in 5% dextrose injection and 0.9% sodium chloride injection in glass, polyvinyl chloride, and polyolefin containers. 1992 Am J Hosp Pharm pmid:1373936
Ochiai T [Advances in the fundamentals and therapeutic use of immunosuppressive agents]. 1992 Arerugi pmid:1374229
Hung DT and Schreiber SL cDNA cloning of a human 25 kDa FK506 and rapamycin binding protein. 1992 Biochem. Biophys. Res. Commun. pmid:1374240
Jayaraman T et al. FK506 binding protein associated with the calcium release channel (ryanodine receptor). 1992 J. Biol. Chem. pmid:1374404
Höllsberg P et al. Characterization of HTLV-I in vivo infected T cell clones. IL-2-independent growth of nontransformed T cells. 1992 J. Immunol. pmid:1374452
Jegasothy BV et al. Tacrolimus (FK 506)--a new therapeutic agent for severe recalcitrant psoriasis. 1992 Arch Dermatol pmid:1376102
Wiederrecht G et al. Isolation of a human cDNA encoding a 25 kDa FK-506 and rapamycin binding protein. 1992 Biochem. Biophys. Res. Commun. pmid:1376117
Bernstein L and Daviss SR Organic anxiety disorder with symptoms of akathisia in a patient treated with the immunosuppressant FK506. 1992 Gen Hosp Psychiatry pmid:1376291
Hatfield SM et al. Rapamycin and FK506 differentially inhibit mast cell cytokine production and cytokine-induced proliferation and act as reciprocal antagonists. 1992 J. Pharmacol. Exp. Ther. pmid:1376361
Ericzon BG et al. The effect of FK506 treatment on pancreaticoduodenal allotransplantation in the primate. 1992 Transplantation pmid:1376501
Tze WJ et al. FK 506--an effective immunosuppressant in achieving long-term functional islet allograft survival in diabetic rats. 1992 Transplant. Proc. pmid:1376509
Yasunami Y et al. Induction of donor-specific unresponsiveness in rat islet allografts by FK 506. 1992 Transplant. Proc. pmid:1376510
Kai N et al. A study on the timing of immunologic priming in autoimmune insulitis in NOD mice. 1992 Transplant. Proc. pmid:1376511
Ricordi C et al. Effect of FK 506 on human pancreatic islets following renal subcapsular transplantation in diabetic nude mice. 1992 Transplant. Proc. pmid:1376512
Hisanaga M et al. Successful combination therapy with FK 506 and 15-deoxyspergualin in pancreatic islet xenografting. 1992 Transplant. Proc. pmid:1376513
Ogasa N et al. Successful transplantation of newborn rat intestine as a free graft. 1992 Transplant. Proc. pmid:1376514
Graeb C et al. Cytoimmunologic monitoring of small bowel allograft recipients. 1992 Transplant. Proc. pmid:1376515
Date K et al. Effect of FK 506 on graft survival in rat small intestinal allografts. 1992 Transplant. Proc. pmid:1376516
Hatazawa C et al. Effect of FK 506 on bowel transplantation in rats. 1992 Transplant. Proc. pmid:1376517
Jain A et al. Intravenous, oral pharmacokinetics, and oral dosing of FK 506 in small bowel transplant patients. 1992 Transplant. Proc. pmid:1376518
Hirano Y et al. The effects of FK506 and cyclosporine on the exocrine function of the rat pancreas. 1992 Transplantation pmid:1279850
Takaya S et al. Liver transplantation in positive cytotoxic crossmatch cases using FK506, high-dose steroids, and prostaglandin E1. 1992 Transplantation pmid:1279851
Partaledis JA et al. Saccharomyces cerevisiae contains a homolog of human FKBP-13, a membrane-associated FK506/rapamycin binding protein. 1992 Yeast pmid:1279908
Ozawa K et al. An appraisal of pediatric liver transplantation from living relatives. Initial clinical experiences in 20 pediatric liver transplantations from living relatives as donors. 1992 Ann. Surg. pmid:1280074
Akutsu I et al. [Inhibitory effects of cyclosporin A and FK-506 on eosinophil chemotactic factor activity in culture supernatants of mononuclear cells from asthmatics]. 1992 Arerugi pmid:1280086
Bergstrand H and Lundquist B Human basophil histamine release is differently affected by inhibitors of calmodulin, diacylglycerol kinase and peptidyl prolyl cis-trans isomerase in a secretagogue specific manner. 1992 Allergy pmid:1280915
Barry JM Immunosuppressive drugs in renal transplantation. A review of the regimens. 1992 Drugs pmid:1281071
Stiff DD et al. Metabolism of FK 506 in differentially induced rat liver microsomes. 1992 Res. Commun. Chem. Pathol. Pharmacol. pmid:1281332
Foor F et al. Calcineurin mediates inhibition by FK506 and cyclosporin of recovery from alpha-factor arrest in yeast. 1992 Nature pmid:1281518
Goldfeld AE et al. Transcription of the tumor necrosis factor alpha gene is rapidly induced by anti-immunoglobulin and blocked by cyclosporin A and FK506 in human B cells. 1992 Proc. Natl. Acad. Sci. U.S.A. pmid:1281550
Morikawa K et al. The distinct effects of FK506 on the activation, proliferation, and differentiation of human B lymphocytes. 1992 Transplantation pmid:1281561
Moutabarrik A et al. FK506-induced kidney tubular cell injury. 1992 Transplantation pmid:1281562
Yagihashi A et al. HLA matching effect in liver transplantation. 1992 Transplant. Proc. pmid:1281569
Kobayashi M et al. Posttransplant donor-specific T-lymphocytotoxic antibody in liver transplant patients with a positive crossmatch. 1992 Transplant. Proc. pmid:1281570
Lemster B et al. Cytokine gene expression in murine lymphocytes activated in the presence of FK 506, bredinin, mycophenolic acid, or brequinar sodium. 1992 Transplant. Proc. pmid:1281576
Tocci MJ and Sigal NH Recent advances in the mechanism of action of cyclosporine and FK506. 1992 Curr. Opin. Nephrol. Hypertens. pmid:1285380
Bavandi A et al. Diet-induced dermatitis response of hairless rats to systemic treatment with cyclosporin A (Sandimmun), cyclosporin H and FK506. 1992 Exp. Dermatol. pmid:1285411
High KP and Handschumacher RE Immunity, microbial pathogenesis, and immunophilins: finding the keys, now where are the locks? 1992 Infect Agents Dis pmid:1285413
Akutsu I et al. [Inhibitory effect of inhaled FK-506 on increased bronchial responsiveness and eosinophil infiltration in the airway mucosa]. 1992 Arerugi pmid:1377905
Takaori K et al. A comparative study on immunosuppressive effects of cyclosporin A and FK 506 on peripheral blood lymphocytes in dogs. 1992 Biotherapy pmid:1377926
Murthy JN et al. Radioreceptor assay for quantifying FK-506 immunosuppressant in whole blood. 1992 Clin. Chem. pmid:1377995
Takai K et al. Effects of FK506 on rat thymic epithelial cells; immunohistochemical study. 1992 Thymus pmid:1378235
Dutz JP et al. Effects of cognate peptides on cytolytic and proliferative activities of cloned cytotoxic T lymphocytes. 1992 Int. Immunol. pmid:1378297
Kenmochi T et al. [The effect of FK506 on segmental pancreas allograft in mongrel dogs]. 1992 Nihon Geka Gakkai Zasshi pmid:1378526
Mouzaki A et al. Cyclosporin A and FK506 prevent the derepression of the IL-2 gene in mitogen-induced primary T lymphocytes. 1992 Cytokine pmid:1378764
Ramamoorthy S et al. Selective impairment of taurine transport by cyclosporin A in a human placental cell line. 1992 Pediatr. Res. pmid:1378960
Armitage JM et al. Clinical trial of FK 506 immunosuppression in adult cardiac transplantation. 1992 Ann. Thorac. Surg. pmid:1379032
Thomson AW The spectrum of action of new immunosuppressive drugs. 1992 Clin. Exp. Immunol. pmid:1379130
Fischer G et al. Mip protein of Legionella pneumophila exhibits peptidyl-prolyl-cis/trans isomerase (PPlase) activity. 1992 Mol. Microbiol. pmid:1379319
Rondeau E [Mechanism of action of the new immunosuppressants: cyclosporin A, FK 506 and rapamycin]. 1992 Nephrologie pmid:1379348
Takada K et al. Distribution kinetics of FK-506, a novel immunosuppressant, after intravenous administration to rats in comparison with cyclosporin A. 1992 Biopharm Drug Dispos pmid:1379839
Kahan BD Cyclosporin A, FK506, rapamycin: the use of a quantitative analytic tool to discriminate immunosuppressive drug interactions. 1992 J. Am. Soc. Nephrol. pmid:1379841
Lauerma AI et al. Inhibition of contact allergy reactions by topical FK506. 1992 Lancet pmid:1380111
Steiner JP et al. High brain densities of the immunophilin FKBP colocalized with calcineurin. 1992 Nature pmid:1380130
Aperia A et al. Calcineurin mediates alpha-adrenergic stimulation of Na+,K(+)-ATPase activity in renal tubule cells. 1992 Proc. Natl. Acad. Sci. U.S.A. pmid:1380157
Nielsen JB et al. Yeast FKBP-13 is a membrane-associated FK506-binding protein encoded by the nonessential gene FKB2. 1992 Proc. Natl. Acad. Sci. U.S.A. pmid:1380159
Calvo V et al. Interleukin 2 stimulation of p70 S6 kinase activity is inhibited by the immunosuppressant rapamycin. 1992 Proc. Natl. Acad. Sci. U.S.A. pmid:1380162
Price DJ et al. Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. 1992 Science pmid:1380182
Granelli-Piperno A SRC-related proto-oncogenes and transcription factors in primary human T cells: modulation by cyclosporin A and FK506. 1992 J. Autoimmun. pmid:1380242
Reem GH Molecular mode of action of cyclosporin and FK506 in human thymocytes. 1992 J. Autoimmun. pmid:1380243
Bach JF Immunointervention in autoimmune diseases from cellular selectivity to autoantigen specificity. 1992 J. Autoimmun. pmid:1380245
Baumann G et al. Molecular mechanisms of immunosuppression. 1992 J. Autoimmun. pmid:1380246
Walpoth B et al. Assessment of new immunosuppressive drugs in a rat cardiac allograft heterotopic model. 1992 Eur Surg Res pmid:1380460
Fruman DA et al. Correlation of calcineurin phosphatase activity and programmed cell death in murine T cell hybridomas. 1992 Eur. J. Immunol. pmid:1382988
Mittrücker HW and Fleischer B Functional localization of an exocytosis-triggering G-protein in human cytotoxic T lymphocytes. 1992 Immunology pmid:1383135
Yasutomi D et al. Inhibition of programmed cell death by cyclosporin A; preferential blocking of cell death induced by signals via TCR/CD3 complex and its mode of action. 1992 Immunology pmid:1383138
Ruff VA et al. Tissue distribution and cellular localization of hsp56, an FK506-binding protein. Characterization using a highly specific polyclonal antibody. 1992 J. Biol. Chem. pmid:1383222
Wiederrecht G et al. Characterization of high molecular weight FK-506 binding activities reveals a novel FK-506-binding protein as well as a protein complex. 1992 J. Biol. Chem. pmid:1383226
Morris RE Immunopharmacology of new xenobiotic immunosuppressive molecules. 1992 Semin. Nephrol. pmid:1384096
Hendey B et al. Inhibition of neutrophil chemokinesis on vitronectin by inhibitors of calcineurin. 1992 Science pmid:1384129
Roberti I et al. Evidence that the systematic analysis of bile cytology permits monitoring of hepatic allograft rejection. 1992 Transplantation pmid:1384182
Langrehr JM et al. Evidence that indefinite survival of small bowel allografts achieved by a brief course of cyclosporine or FK506 is not due to systemic hyporesponsiveness. 1992 Transplantation pmid:1384185
McCarthy SA et al. The effects of immunosuppressive drugs on the regulation of activation-induced apoptotic cell death in thymocytes. 1992 Transplantation pmid:1384186
Dhar DK et al. The salutary effect of FK506 in ischemia-reperfusion injury of the canine liver. 1992 Transplantation pmid:1384188
Ericzon BG et al. FK506-induced impairment of glucose metabolism in the primate--studies in pancreatic transplant recipients and in nontransplanted animals. 1992 Transplantation pmid:1384189
Meiser BM et al. Continuous infusion of angiopeptin significantly reduces accelerated graft vessel disease induced by FK 506 in a rat heart allograft model. 1992 Transplant. Proc. pmid:1384201
Wakabayashi H et al. Effect of FK 506 and cyclosporine A on hepatic energy status in the rat after warm ischemia, as monitored by 31P nuclear magnetic resonance spectroscopy in vivo. 1992 Transplant. Proc. pmid:1384205
Griffin AD et al. FK 506 in canine renal transplantation. 1992 Transplant. Proc. pmid:1384209